Lixte Biotechnology (NASDAQ:LIXT) Posts Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) released its quarterly earnings results on Monday. The company reported ($0.27) EPS for the quarter, Zacks reports.

Lixte Biotechnology Trading Up 1.1 %

NASDAQ:LIXT opened at $1.36 on Wednesday. The firm has a fifty day simple moving average of $1.76 and a 200-day simple moving average of $1.88. The company has a market capitalization of $3.05 million, a P/E ratio of -0.78 and a beta of 0.19. Lixte Biotechnology has a 12 month low of $1.02 and a 12 month high of $4.40.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.